Triglav Skladi D.O.O. Invests $2.59 Million in Boston Scientific Co. (NYSE:BSX)

Triglav Skladi D.O.O. acquired a new stake in Boston Scientific Co. (NYSE:BSX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 29,000 shares of the medical equipment provider's stock, valued at approximately $2,590,000.

Several other institutional investors and hedge funds have also recently made changes to their positions in the company. Two Sigma Advisers LP raised its holdings in shares of Boston Scientific by 48.5% in the fourth quarter. Two Sigma Advisers LP now owns 755,260 shares of the medical equipment provider's stock valued at $67,460,000 after acquiring an additional 246,800 shares in the last quarter. Temasek Holdings Private Ltd bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $36,308,000. Tidal Investments LLC raised its holdings in shares of Boston Scientific by 38.6% in the fourth quarter. Tidal Investments LLC now owns 119,876 shares of the medical equipment provider's stock valued at $10,707,000 after acquiring an additional 33,369 shares in the last quarter. State of Wyoming raised its holdings in shares of Boston Scientific by 119.5% in the fourth quarter. State of Wyoming now owns 2,660 shares of the medical equipment provider's stock valued at $238,000 after acquiring an additional 1,448 shares in the last quarter. Finally, Tema Etfs LLC bought a new stake in shares of Boston Scientific in the fourth quarter valued at about $1,831,000. 89.07% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Boston Scientific

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,572 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $104.54, for a total value of $477,956.88. Following the completion of the transaction, the executive vice president now directly owns 18,705 shares of the company's stock, valued at approximately $1,955,420.70. The trade was a 19.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Jeffrey B. Mirviss sold 4,675 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $104.25, for a total value of $487,368.75. Following the completion of the transaction, the executive vice president now directly owns 28,454 shares of the company's stock, valued at $2,966,329.50. The trade was a 14.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 195,830 shares of company stock valued at $20,043,415. 0.50% of the stock is owned by company insiders.

Analysts Set New Price Targets

BSX has been the topic of several analyst reports. Piper Sandler lifted their target price on Boston Scientific from $95.00 to $115.00 and gave the company an "overweight" rating in a research note on Monday, February 3rd. UBS Group lifted their target price on Boston Scientific from $105.00 to $130.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Argus set a $130.00 target price on Boston Scientific in a research note on Tuesday, February 18th. BTIG Research reiterated a "buy" rating and issued a $124.00 target price on shares of Boston Scientific in a research note on Wednesday, April 23rd. Finally, Stifel Nicolaus lifted their target price on Boston Scientific from $100.00 to $115.00 and gave the company a "buy" rating in a research note on Thursday, February 6th. Twenty-three investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $114.87.

Boston Scientific Stock Performance

NYSE BSX traded down $0.01 during trading hours on Friday, reaching $104.49. The stock had a trading volume of 5,205,948 shares, compared to its average volume of 6,387,568. The stock has a fifty day moving average of $99.97 and a 200 day moving average of $97.29. The stock has a market cap of $154.59 billion, a P/E ratio of 83.59, a price-to-earnings-growth ratio of 2.79 and a beta of 0.68. Boston Scientific Co. has a 52-week low of $71.88 and a 52-week high of $107.17. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.02 and a current ratio of 1.08.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. The firm had revenue of $4.66 billion for the quarter, compared to analyst estimates of $4.57 billion. During the same quarter in the prior year, the firm earned $0.56 earnings per share. Boston Scientific's revenue for the quarter was up 20.9% on a year-over-year basis. Sell-side analysts predict that Boston Scientific Co. will post 2.85 earnings per share for the current year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.